MedTrace Logo

Safety of CRIS100 on Treatment Spinal Cord Injury

NCT05739734 · Status: NOT_YET_RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2026-02-03

No results posted yet for this study

Summary

The goal of this clinical trial is to test CRIS100 treatment in participants with acute thoracic spinal cord injury. The main questions it aims to answer are:

* safety of CRIS100
* efficacy of CRIS100

Participants will receive 100 mcg CRIS100 in the epicenter of the spinal injury, within 72 hours of the trauma.

Conditions

  • Thoracic Spinal Cord Injury

Interventions

DRUG

CRIS100

local application of CRIS100

Sponsors & Collaborators

  • Cristália Produtos Químicos Farmacêuticos Ltda.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-30
Primary Completion
2027-05-31
Completion
2027-05-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05739734 on ClinicalTrials.gov